The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $868,776 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Children's Hospital Corporation, doing business as Boston Children's Hospital, to characterize the role of a novel post-transcriptional regulator, PHAF, in controlling virulence of the opportunistic pathogen Pseudomonas aeruginosa. The research aims to identify PHAF's regulatory targets, elucidate its mechanism of action, and assess its impact on P. aeruginosa virulence under both standard laboratory conditions and infection-relevant environments, including an animal model. This work is expected to enhance understanding of post-transcriptional control mechanisms in this clinically important bacterium. The grant has an award date of February 25, 2025 and a scheduled completion date of January 31, 2030.
Generated 3/25/25, 5:20 AM